NO20081314L - Anvendelse av azabicykloheksanderivater - Google Patents

Anvendelse av azabicykloheksanderivater

Info

Publication number
NO20081314L
NO20081314L NO20081314A NO20081314A NO20081314L NO 20081314 L NO20081314 L NO 20081314L NO 20081314 A NO20081314 A NO 20081314A NO 20081314 A NO20081314 A NO 20081314A NO 20081314 L NO20081314 L NO 20081314L
Authority
NO
Norway
Prior art keywords
disorder
nervosa
hyperchondriasis
sydeham
paraphilia
Prior art date
Application number
NO20081314A
Other languages
English (en)
Inventor
Dieter Hamprecht
Christian Heidbreder
Sergio Melotto
Fabrizio Micheli
Tadataka Yamada
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20081314L publication Critical patent/NO20081314L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives en ny anvendelse av en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt eller solvat derav, der G er valgt fra gruppen bestående av: fenyl, pyridyl, benzotiazolyl, indazolyl; p er et heltall fra 0 til 5; R1 uavhengig er valgt fra en gruppe bestående av: halogen, hydroksyl, cyano, C1-4 alkyl, haloC1-4 a1kyl, C1-4 alkoksy, haloC1-4 alkoksy, C1-4 alkanoyl; eller tilsvarer en gruppe R5; R2 er hydrogen eller C1-4 alkyl; R3 er C1-4 alkyl; R4 er hydrogen, eller en fenylgruppe, en heterocyklylgruppe, en 5- eller 6-leddet heteroaromatisk gruppe, eller en 8- til 11-leddet bicyklisk gruppe der disse grupper eventuelt er substituert med 1, 2, 3 eller 4 substituenter valgt fra gruppen bestående av: halogen, cyano, C1-4 alkyl, haloC1-4 alkyl, C1-4 alkoksy, C1-4 alkanoyl; R5 er en del valgt fra gruppen bestående av: isoksazolyl, -CH2-N-pyrrolyl, 1,1-dioksido-2-isotiazolidinyl, tienyl, tiazolyl, pyridyl, 2-pyrrolidinonyl, og en slik gruppe eventuelt er substituert med en eller to substituenter valgt blan t: halogen, cyano, C1-4 alkyl, haloC1-4 alkyl, C1-4 alkoksy, C1-4 alkanoyl; og når R1 er klor og p er 1, er slik R1 ikke til stede i ortoposisjon med henblikk på forbindelsesbindingen til resten av molekylet; og når R1 tilsvarer R5 er p lik l; ved fremstillingen av et medikament for behandlingen av en somatoform forstyrrelse som kroppsdysmorfisk forstyrrelse eller hyperkondriasis, bulimia nervosa, anoreksia nervosa, tvangsspising, parafilia og ikke-parafile seksuelle addiksjoner, Sydehams korea, tortikollis, autisme, en bevegelsesforstyrrelse inkludert Tourettes syndrom; og ved fremstilling av et medikament for behandling av prematur ejakulasjon.
NO20081314A 2005-08-22 2008-03-12 Anvendelse av azabicykloheksanderivater NO20081314L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517193.9A GB0517193D0 (en) 2005-08-22 2005-08-22 Novel use
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives

Publications (1)

Publication Number Publication Date
NO20081314L true NO20081314L (no) 2008-03-17

Family

ID=35098098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081314A NO20081314L (no) 2005-08-22 2008-03-12 Anvendelse av azabicykloheksanderivater

Country Status (20)

Country Link
US (2) US20090036461A1 (no)
EP (1) EP1917013B1 (no)
JP (1) JP5166267B2 (no)
KR (1) KR101363090B1 (no)
CN (1) CN101291669B (no)
AT (1) ATE500826T1 (no)
AU (1) AU2006284077B2 (no)
BR (1) BRPI0614929A2 (no)
CA (1) CA2620090A1 (no)
CR (1) CR9807A (no)
DE (1) DE602006020589D1 (no)
EA (1) EA016084B1 (no)
ES (1) ES2361933T3 (no)
GB (1) GB0517193D0 (no)
IL (1) IL189435A0 (no)
MA (1) MA29774B1 (no)
MX (1) MX2008002564A (no)
NO (1) NO20081314L (no)
WO (1) WO2007022980A1 (no)
ZA (1) ZA200801352B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
NZ592836A (en) * 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
BR112012000657A2 (pt) * 2009-06-26 2016-11-16 Panacea Biotec Ltd novos azabicilohexanos
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US9314600B2 (en) 2012-04-15 2016-04-19 Bioconnect Systems, Inc. Delivery system for implantable flow connector
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
SE526837C2 (sv) * 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
AU2005311452A1 (en) * 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR060237A1 (es) * 2006-04-03 2008-06-04 Glaxo Group Ltd Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CN101291669A (zh) 2008-10-22
US20090036461A1 (en) 2009-02-05
CN101291669B (zh) 2012-09-26
ZA200801352B (en) 2009-01-28
EP1917013B1 (en) 2011-03-09
EA016084B1 (ru) 2012-02-28
KR101363090B1 (ko) 2014-02-13
US20120196910A1 (en) 2012-08-02
GB0517193D0 (en) 2005-09-28
JP5166267B2 (ja) 2013-03-21
AU2006284077A1 (en) 2007-03-01
CR9807A (es) 2008-07-29
MX2008002564A (es) 2008-03-18
BRPI0614929A2 (pt) 2011-04-19
KR20080040022A (ko) 2008-05-07
EA200800655A1 (ru) 2008-08-29
IL189435A0 (en) 2008-08-07
AU2006284077B2 (en) 2012-05-17
JP2009506989A (ja) 2009-02-19
ATE500826T1 (de) 2011-03-15
DE602006020589D1 (de) 2011-04-21
ES2361933T3 (es) 2011-06-24
MA29774B1 (fr) 2008-09-01
EP1917013A1 (en) 2008-05-07
CA2620090A1 (en) 2007-03-01
WO2007022980A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20081314L (no) Anvendelse av azabicykloheksanderivater
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
GB0612423D0 (en) Therapeutic agents
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MX2009001062A (es) Agonistas de ep2.
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
EA201290229A1 (ru) Производные спиролактама и их применение
ATE368040T1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
IL191928A0 (en) Triazoloanilinopyrimidine derivatives for use as antiviral agents
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
NO20080501L (no) Kinolinderivater som antibakterielle midler
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
EA200800151A1 (ru) Производные хинолина в качестве антибактериальных агентов
UA94953C2 (en) Ep2 agonists

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application